X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DIOS-202,DIOS-203
Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-202
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CV7301
Therapeutic Area: Infections and Infectious Diseases Product Name: CV7301
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $1,100.0 million Upfront Cash: $147.1 million
Deal Type: Collaboration July 20, 2020
Details:
Under the terms of the agreement, GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration and CureVac will be responsible for the preclinical- and clinical development through Phase 1 trials of these projects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Povidone-Iodine
Therapeutic Area: Infections and Infectious Diseases Product Name: Betadine
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Testing has demonstrated BETADINE's® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, Skin Cleanser, Gargle and Mouthwash and Throat Spray.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgY antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the infection process. IgNova's technology offers a safe, economical, and unlimited source of polyclonal antibodies to control SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a major criterion supporting that the vaccine candidate has the potential to induce a strong immunologic response.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
